Solid Tumor - Shenzhen Genoimmune Medical Institute

Solid Tumor

Trial title

Estimated Enrollment

Partner
Trial title

Multicenter Trial of Phase I/II Studies on GD2 Positive Solid Tumors by 4SCAR-GD2' NCT02992210

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Interventional Treatment of Ovarian Cancer(OC) With OC Immunogene-modified T Cells(OC-lgT)' NCT03184753

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Immunogene-modified Antigen-specific T(lgT) Cells for the Treatment of Glioblastoma Multiforme' NCT03170141

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies' NCT03185468

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas' NCT03356782

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer' NCT03356795

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Engineered Immune Effectors Against Ovarian Cancer' NCT03362606

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Engineered Immune Effectors Against Cervical Cancer' NCT03362619

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Lung Cancer' NCT03356808

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Tumor Associated Antigen-specific Engineered Immune Effector Cells (EIE) Against Cancer' NCT03535246

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Antigen-specific Engineered Immune Effector Cells (EIE) Against Gastro-Intestinal (GI) Cancer' NCT03614650

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Immune Modulatory DC Vaccine Against Brain Tumor' NCT03914768

Estimated Enrollment

10

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis Type II or Schwannomatosis' NCT04085159

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Phase I/II Clinical Trial of 4SCAR-PSMA T Cell Therapy Targeting PSMA Positive Malignancies' NCT04429451

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multiple 4SCAR-T Cell Therapy Targeting Breast Cancer' NCT04430595

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Safety and Efficacy Evaluation of a Combination Immunotherapy Targeting Sarcomas' NCT04433221

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multicenter Trial of Phase I/II Studies on CD276 (B7-H3) Positive Solid Tumors Treated With 4SCAR-276' NCT04432649

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

GD2/PSMA Bi-specific CAR-T Cells For the Treatment of GD2 and PSMA Positive Solid Tumors' NCT05437315

Estimated Enrollment

60

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

PSMA/CD70 Bi-specific CAR-T Cells For the Treatment of PSMA and CD70 Positive Solid Tumors' NCT05437341

Estimated Enrollment

60

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

GD2/CD70 Bi-specific CAR-T Cells For the Treatment of GD2 and CD70 Positive Solid Tumors' NCT05438368

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

GD2/CD56 Bi-specific CAR-T Cells For the Treatment of GD2 and CD56 Positive Solid Tumors' NCT05437328

Estimated Enrollment

60

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Development of Prostate Cancer Dendritic Cell Vaccines' NCT07068555

Estimated Enrollment

10

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

DLL3 CAR-T Therapy Targeting Brain Tumors' NCT07180927

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

NG2 and DLL3 CAR-T Cells Targeting Melanoma' NCT07193966

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute